Strategic Communication and Public Relations

Using oxygen to make cancer visible

No. 08 | 18/02/2020 | by Rei

Scientists from the German Cancer Research Center have developed a new method that uses oxygen to identify brain tumors more effectively by magnetic resonance tomography (MRT). To do so, they rely on a metabolic feature of the tumor cells that they can make visible using a completely new imaging method. The researchers hope that the new technique will help further improve the diagnosis and characterization of brain tumors in future.

The red line delineates the tumor area; the colored contrast shows the oxygen metabolism. As predicted by Warburg’s theory, oxygen turnover in the tumor is reduced (blue).
© Paech / Radiology

Tumor cells differ considerably from healthy tissue in terms of their metabolism, as discovered by the German physician and biochemist Otto Heinrich Warburg back in the 1920s. He observed an accumulation of lactic acid in tumor cells. This metabolic product is the result of the anaerobic metabolism (i.e., without oxygen) that tumor cells prefer, even if enough oxygen is available. This phenomenon became known as the Warburg effect.

"We wondered whether this feature could be made visible on MRT," explained Daniel Paech, a physician and physicist at the German Cancer Research Center (DKFZ) in Heidelberg. Traditional MRT scans can only make structural changes visible.

The new method developed by the DKFZ researchers does not require radioactivity and shows the oxygen-dependent metabolism of the tissue very specifically. The researchers use a stable, non-radioactive oxygen isotope, 17O2, which is present in small quantities in the air. The test subjects breathe in this special oxygen in an enriched form. Everywhere where oxygen is metabolized in body tissue, 17O2 forms a compound with hydrogen. That means that it can be demonstrated in the MRT magnetic field. Tissue that metabolizes a large amount of oxygen thus appears light on the image.

Daniel Paech, his colleague Sebastian Niesporek, and their team of researchers at DKFZ began by trying out the principle in three healthy subjects. As expected, a high oxygen turnover was seen in their brains. The researchers then used the new oxygen MRT to examine ten individuals who had been diagnosed as having a brain tumor. "The result was really impressive: The tumors appeared on the images as dark spots because there was no oxygen metabolism there," Paech remarked. "We were surprised that this was the case both in aggressive higher-grade tumors and in less aggressive low-grade tumors," he added. It was not previously clear whether the Warburg effect plays a role in low-grade brain tumors too.

The DKFZ researchers have not only obtained new findings on the biology of brain tumors; they have also developed a method capable of characterizing tumor tissue more accurately. "We see the method as supplementing structural MRT imaging to show differences between tumor and healthy tissue," Paech explained. "The additional information might help characterize tumors more precisely in future on the basis of their particular metabolism."

A comparable technology currently only exists for PET – with the disadvantage that it requires the radioactive oxygen isotope 15O2. Moreover, this isotope needs to be produced on site using considerable resources, which is only possible at a few hospitals.

Even with the new MRT method devised by the DKFZ researchers, there are still some problems that need to be solved before it can be used in clinical practice. Enriched 17O2 is still very expensive, although Paech assumes that the production costs may drop if the molecule were to be produced on a larger scale.

"In future, clinical studies need to be carried out," Paech commented. "They are necessary to see whether 17O2 can be approved and to demonstrate the clinical benefit of the method," he continued.

The new method was developed using DKFZ's 7T MRT as part of collaboration between the Division of Radiology and the Division of Medical Physics in Radiology and was awarded the Roland Ernst Prize for Interdisciplinary Research in Radiology in December last year. The researchers expect oxygen MRT to provide valuable information about other diseases associated with metabolic changes in future too, such as Alzheimer's disease and multiple sclerosis.

Daniel Paech, Armin M. Nagel, Miriam N. Schultheiss, Reiner Umathum, Sebastian Regnery, Moritz Scherer, Antje Wick, MD Tanja Platt, Wolfgang Wick, Martin Bendszus, Andreas Unterberg, Heinz-Peter Schlemmer, Mark E. Ladd, Sebastian C. Niesporek: Quantitative dynamic oxygen-17 MRI at 7-T for cerebral oxygen metabolism in glioma
Radiology 2020, DOI: https://doi.org/10.1148/radiol.2020191711

A photo is available for download at:
www.dkfz.de/de/presse/pressemitteilungen/2020/bilder/Niesporek_17OPat_POF.jpg 
Photo caption: The red line delineates the tumor area; the colored contrast shows the oxygen metabolism. As predicted by Warburg's theory, oxygen turnover in the tumor is reduced (blue).

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: Paech / Radiology".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS